This Ratio Explains Why I’d Buy AstraZeneca plc Today

AstraZeneca plc (LON:AZN) offers a 5.4% yield, but there’s a more compelling reason to buy this firm’s shares, as Roland Head explains.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

AstraZeneca (LSE: AZN) (NYSE: AZN.US) has been much abused for its failure to invest in new products during the reign of ex-CEO David Brennan, and is undoubtedly suffering the consequences now, with both sales and earnings expected to fall for the next couple of years.

However, I reckon that investors might be overlooking one key factor, which suggests that AstraZeneca is already outrageously cheap compared to GlaxoSmithKline — and that now could be a cracking time to buy into Astra.

An important ratio

The faithful price-to-earnings ratio is a great tool for comparing the price of two similar companies, but sometimes it doesn’t tell the whole story. One problem in particular is with debt — the P/E ratio only looks at market capitalisation, and does not reflect a company’s debt levels.

For this reason, anyone considering buying a company usually shuns the P/E ratio and instead calculates the enterprise value to EBITDA ratio. Enterprise value is the true cost of a company — the sum of its market capitalisation and net debt — while EBITDA is earnings before interest, tax, depreciation and amortisation, which provides a measure of a firm’s raw profits.

By now you’ve probably guessed what’s coming — on an EV/EBITDA basis, AstraZeneca is exactly half the price of GlaxoSmithKline.

Why is AstraZeneca so cheap?

AstraZeneca currently boasts a modest EV/EBITDA ratio of 5.6, while Glaxo trades on a heady EV/EBITDA of 11.2.

Some of this pricing discrepancy can be accounted for by the fact that, unlike Astra, Glaxo has largely recovered from the patent cliff. But there must be another explanation, as well.

I think that the real reason for this massive difference in valuation is debt. Borrowing costs for big companies are low at the moment, and markets seem to be ignoring the risk that borrowing might become more expensive in the future, or that profits might fall, making it harder for companies to service their debts and pay dividends.

Glaxo has net debt of £15.7bn, giving it net gearing of 245%. AstraZeneca, in contrast, had net cash until the end of 2011, and currently has net gearing of just 5.6%.

This difference isn’t reflected in the valuations of the two companies, but I think it will be eventually, making AstraZeneca a very affordable and safe buy today, despite its short-term earnings weakness.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

> Roland owns shares in GlaxoSmithKline but does not own shares in AstraZeneca. The Motley Fool has recommended GlaxoSmithKline.

More on Investing Articles

Investing Articles

3 world-class stocks to consider buying, while they’re ‘on sale’

Looking for stocks to buy? These three all have attractive long-term prospects and are currently trading 20% or more below…

Read more »

Smart young brown businesswoman working from home on a laptop
Investing Articles

Could BP’s share price rebound over the next 12 months? These analysts think the answer is ‘yes’!

BPs share price has plummeted over the last year. But City brokers think things are about to turn around, as…

Read more »

Investing Articles

Is this an unmissable opportunity to buy Nvidia stock?

Nvidia stock is down 33% from its peak, driven by tariffs and geopolitical pressures. Despite this, some investors may spy…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

Dividend investors! Here’s what Warren Buffett says builds wealth in the stock market

Reinvesting dividends at yields of 8% or higher looks like a good way of building wealth. But Warren Buffett has…

Read more »

Calendar showing the date of 5th April on desk in a house
Investing Articles

Here’s my Stocks and Shares ISA plan for 2025-26

A Stocks and Shares ISA helps investors avoid taxes on dividends and capital gains. And Stephen Wright has a plan…

Read more »

Dividend Shares

Of the 20 highest-yielding FTSE 100 stocks, this is my top pick

This FTSE 100 stock currently offers a yield of 6.4%. But Edward Sheldon believes it’s capable of providing share price…

Read more »

Investing Articles

Could Tesla’s share price jump over the next 12 months? These analysts think so!

Tesla's share price has fallen by almost a third since 1 January. But optimism is high that Elon Musk's company…

Read more »

Investing Articles

I asked ChatGPT where the FTSE 100 will be in 6 months: here’s what it said…

Let’s be realistic, ChatGPT can’t predict the future. But it did do a good job of compiling data from brokerages…

Read more »